BHC Stock Analysis: Buy, Sell, or Hold?
BHC - Bausch Health Companies Inc
$7.00
0.11 (1.60%)
▲
5d:
+56.25%
30d:
+42.86%
90d:
+23.89%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Smart Money Distribution
None View Scanner →
Strength: 8.0/10
Get Alerted When BHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: BHC is 24.8% above its trading range ($5.61). Market expects 8.6% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: BHC is 24.8% above its trading range ($5.61). Market expects 8.6% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$4.68
Based on -2.9% avg growth
INTRINSIC VALUE TODAY
$2.90
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BHC is currently trading at $7.00, which is considered extended relative to its 30-day fair value range of $4.34 to $5.61. From a valuation perspective, the stock is trading at a premium (Forward PE: 1.8) compared to its historical average (1.4). At these levels, the market is pricing in 8.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BHC is in a strong uptrend. Immediate support is located at $4.33, while resistance sits at $7.30.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BHC is in a strong uptrend. Immediate support is located at $4.33, while resistance sits at $7.30.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.34 -
$5.61
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
36.7%
Protect Your Profits
BHC is technically overbought (RSI 81). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+24.8% above its trading range)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($7.50)
- NEUTRAL: PE elevated vs history but 8.6% growth expectation is conservative given 1368% recent growth
Trading Range Analysis
30-Day Trading Range
$4.34 -
$5.61
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.33
Resistance Level
$7.30
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.77
Wall Street Target
$7.50
(+8.9%)
Revenue Growth (YoY)
11.7%
Earnings Growth (YoY)
1368.0%
Profit Margin
-11.5%
Valuation Premium vs History
+8.6% premium
PE vs Historical
1.8 vs 1.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.6%
(market-implied from PE analysis)
1-Year Target
$7.48
(+9%)
2-Year Target
$8.13
(+18%)
3-Year Target
$8.82
(+28%)
3-Yr Target (if PE normalizes)
(PE: 2→1)
PE COMPRESSION
$6.96
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: -9.7%)
$59.26
(+760%)
Base:
(SPY PE: 1.8, Growth: -9.7%)
$5.07
(-26%)
Bear:
(PE: 1.4, Growth: -9.7%)
$4.00
(-42%)
Share & Embed Analysis
Last updated: August 03, 2026 4:23 PM ET
Data refreshes hourly during market hours. Next update: 5:23 PM
Data refreshes hourly during market hours. Next update: 5:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced BHC Option Strategies
Professional options setups generated by AI based on today's BHC price and gamma walls.
